Human Genome Sciences today announced that it will receive a $40 million payment from Novartis in September 2007 for the previously reported successful completion of a Phase 2b trial of Albuferon(R) (albinterferon alfa-2b) in treatment-naive patients with chronic hepatitis C. “This $40 million payment will bring the total milestone payments received from Novartis under our [...]
Continue reading " Human Genome Sciences Announces $40 Million Payment "

